For NSCLC with driver gene mutations/translocations, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase, the BRAF and ROS1 genes, first-line therapy with tyrosine kinase inhibitors (TKIs) targeting the respective gene mutations/translocations is usually recommended. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.